Affordable Access

Access to the full text

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia

Authors
  • Fransecky, Lars1
  • Mochmann, Liliana H1
  • Baldus, Claudia D1
  • 1 Charité University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany , Berlin (Germany)
Type
Published Article
Journal
Molecular and Cellular Therapies
Publisher
"ClinTransMed, AB"
Publication Date
Mar 20, 2015
Volume
3
Issue
1
Identifiers
DOI: 10.1186/s40591-015-0040-8
Source
Springer Nature
Keywords
License
Green

Abstract

Technological advances allowing high throughput analyses across numerous cancer tissues have allowed much progress in understanding complex cellular signaling. In the future, the genetic landscape in cancer may have more clinical relevance than diagnosis based on tumor origin. This progress has emphasized PI3K/AKT/mTOR, among others, as a central signaling center of cancer development due to its governing control in cellular growth, survival, and metabolism. The discovery of high frequencies of mutations in the PI3K/AKT/mTOR pathway in different cancer entities has sparked interest to inhibit elements of this pathway. In acute leukemia pharmacological interruption has yet to achieve desirable efficacy as targetable downstream mutations in PI3K/AKT/mTOR are absent. Nevertheless, mutations in membrane-associated genes upstream of PI3K/AKT/mTOR are frequent in acute leukemia and are associated with aberrant activation of PI3K/AKT/mTOR thus providing a good rationale for further exploration. This review attempts to summarize key findings leading to aberrant activation and to reflect on both promises and challenges of targeting PI3K/AKT/mTOR in acute leukemia. Our emphasis lies on the insights gained through high-throughput data acquisition that open up new avenues for identifying specific subgroups of acute leukemia as ideal candidates for PI3K/AKT/mTOR targeted therapy.

Report this publication

Statistics

Seen <100 times